Johnson & Johnson has put in a $27 billion bid for the Swiss biotech Actelion, and competitor Sanofi may submit a counterbid, people familiar with the matter said. Jean-Paul Clozel, Actelion’s co-founder, has said he’d prefer to keep the company independent, but a person with knowledge of the discussions said he might be receptive if the offer is high enough.